Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

BIOCHIP autoantibody enzyme-linked immunoassay immunoblot type VII collagen epidermolysis bullosa acquisita

Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
23 Mar 2021
Historique:
pubmed: 10 3 2021
medline: 24 6 2021
entrez: 9 3 2021
Statut: epublish

Résumé

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen non-collagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, follow-ed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Identifiants

pubmed: 33686442
doi: 10.2340/00015555-3774
pmc: PMC9366678
doi:

Substances chimiques

Autoantibodies 0
Collagen Type VII 0

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv00420

Références

Orphanet J Rare Dis. 2018 Sep 4;13(1):153
pubmed: 30180870
J Clin Invest. 1993 Oct;92(4):1831-9
pubmed: 7691888
J Am Acad Dermatol. 2016 Jun;74(6):1166-72
pubmed: 26947449
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-1913
pubmed: 32830877
Exp Dermatol. 2017 Dec;26(12):1154-1162
pubmed: 28887824
Expert Rev Clin Immunol. 2017 Feb;13(2):157-169
pubmed: 27580464
Arch Dermatol Res. 2016 May;308(4):273-6
pubmed: 26895535
N Engl J Med. 1984 Apr 19;310(16):1007-13
pubmed: 6369131
Br J Dermatol. 2004 May;150(5):843-51
pubmed: 15149495
Gene Ther. 2010 Jul;17(7):930-7
pubmed: 20376098
J Clin Invest. 1988 Mar;81(3):683-7
pubmed: 3278005
J Am Acad Dermatol. 2021 Apr;84(4):1155-1157
pubmed: 32711089
Br J Dermatol. 1984 Jan;110(1):1-7
pubmed: 6362707
Autoimmun Rev. 2019 Aug;18(8):786-795
pubmed: 31181325
Br J Dermatol. 2013 Jul;169(1):164-7
pubmed: 23480491
Br J Dermatol. 2018 Jul;179(1):30-41
pubmed: 29165796
J Invest Dermatol. 1996 Jun;106(6):1333-8
pubmed: 8752680
Hum Gene Ther. 2002 Sep 1;13(13):1655-62
pubmed: 12228020
J Dtsch Dermatol Ges. 2020 May;18(5):516-526
pubmed: 32413212
Br J Dermatol. 2013 Jul;169(1):100-5
pubmed: 23489262
Br J Dermatol. 2011 Jan;164(1):76-82
pubmed: 20854435
J Am Acad Dermatol. 2014 Jul;71(1):185-91
pubmed: 24767733
J Invest Dermatol. 2016 Jan;136(1):24-33
pubmed: 26763420
Expert Rev Clin Immunol. 2016 Aug;12(8):895-902
pubmed: 27247994
Br J Dermatol. 2017 Dec;177(6):1683-1692
pubmed: 28703393
J Am Acad Dermatol. 2018 Apr;78(4):754-759.e6
pubmed: 29154993
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):e224-30
pubmed: 22731917
J Dermatol Sci. 2011 Jun;62(3):169-75
pubmed: 21482078
Br J Dermatol. 2009 Aug;161(2):306-12
pubmed: 19485996
J Am Acad Dermatol. 2013 Mar;68(3):e89-95
pubmed: 22341608
Eur J Dermatol. 2016 Jan-Feb;26(1):56-63
pubmed: 26771500
Front Med (Lausanne). 2019 Jan 10;5:362
pubmed: 30687710
J Invest Dermatol. 2016 Dec;136(12):2495-2498
pubmed: 27456755
Br J Dermatol. 2019 Jan;180(1):149-156
pubmed: 30216412
J Biol Chem. 2002 Jan 18;277(3):2118-24
pubmed: 11698408
J Am Acad Dermatol. 2019 Nov;81(5):1195-1197
pubmed: 30953703
J Eur Acad Dermatol Venereol. 2014 Apr;28(4):483-90
pubmed: 24321031
Br J Dermatol. 2018 Feb;178(2):573
pubmed: 28977674
Mol Ther. 2010 Aug;18(8):1509-18
pubmed: 20485266
Br J Dermatol. 2004 Jul;151(1):112-8
pubmed: 15270879

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH